Oncolys BioPharma announced that it obtained approval for the manufacturing and sale of the esophageal cancer treatment drug ‘Telomerasin Injection,’ a tumor dissolving virus, on June 8, 2026, with sales scheduled to commence from the December 2026 fiscal year. The company disclosed clinical trial results and future revenue projections.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4588-20260608-01.pdf","jir_short_summary":"Oncolys BioPharma announced that it obtained approval for the manufacturing and sale of the esophageal cancer treatment drug 'Telomerasin Injection,' a tumor dissolving virus, on June 8, 2026, with sales scheduled to commence from the December 2026 fiscal year. The company disclosed clinical trial results and future revenue projections.","jir_summary":"### Performance Overview\nOncolys BioPharma announced that it has obtained approval for the manufacturing and sale of the tumor dissolving virus 'Telomerasin Injection' targeting esophageal cancer on June 8, 2026. This is the world's first tumor dissolving adenovirus product for esophageal cancer, developed based on clinical trial results from 17 domestic facilities, and received standard approval upon application. Sales are scheduled to start from the December 2026 fiscal year after drug pricing is listed, with expectations to contribute to future revenue. Following the approval, the company will receive milestone income from Fujifilm Toyama Chemical, and pre-receipt of funds is anticipated within this fiscal year. The specific impact on performance for this fiscal year remains undecided.\n\n### Future Outlook and Investor Impact\nThe company aims to contribute to the expansion of the esophageal cancer treatment market by providing a new treatment option through this approval. Preparations for sales are underway, with revenue recognition expected from the December 2026 fiscal year. Future revenue realization and clinical data progress are critical factors that could enhance corporate value. For investors, this milestone marks significant progress from clinical development to commercialization, and attention will be focused on the start of sales and revenue generation.","jir_financial_highlights":"Milestone Revenue: Unknown (Expected to be received within this fiscal year)\nAdvances (Contract Liabilities): Unknown (Recognized as sales after sales commence)","jir_category":"","jir_hashtags":"#OncolysBioPharma, #Earnings, #JapaneseStocks","jir_key_figures":"Milestone Revenue: Unknown (scheduled to be recognized in the December 2026 fiscal year)\nAdvances (Contract Liabilities): Unknown (recognized as sales after sales commence)\nApproval Date: June 8, 2026","jir_meta_title":"\u3010Oncolys BioPharma\u3011Tumor Dissolving Virus Approval\uff5cJune 2026","jir_meta_description":"Oncolys BioPharma obtained approval for the esophageal cancer treatment drug on June 8, 2026, with sales scheduled to start in the December 2026 fiscal year. Focus on future revenue generation.","jir_og_title":"\u3010Oncolys\u3011Tumor Dissolving Virus Approval\uff5cJune 2026","jir_og_description":"Oncolys BioPharma obtained approval for the esophageal cancer treatment drug on June 8, 2026, and is preparing for sales launch. Attention to future developments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-62197","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n